Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission—Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Gorin, Norbert Claude; Labopin, Myriam; Czerw, Tomasz; Pabst, Thomas; Blaise, Didier; Dumas, P; Nemet, Damir; Arcese, William; Trisolini, Silvia Maria; Wu, Depei; Huynh, Anne; Zuckerman, Tsila; Meijer, Ellen; Cagirgan, Seckin; Cornelissen, Jan J.; Houhou, Mohamed; Polge, Emmanuelle; Mohty, Mohamad; Nagler, Arnon

doi:10.1002/cncr.30400

Cited by 34 publications

(20 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…55 A retrospective study reported better RFS and OS in patients receiving busulfan/melphalan conditioning before autoHCT compared with busulfan/cyclophosphamide conditioning. 56 Patients treated with CPX-351 during induction may receive up to 2 consolidation cycles with CPX-351 with a reduced dose and 2 instead of 3 days of application compared with induction ChT. 43 In FLT3-mutated patients, midostaurin is combined with consolidation ChT and up to 3 consolidation cycles should be applied in patients not undergoing alloHCT.…”

Section: Consolidation Treatment With Cht or Autologous Hctmentioning

confidence: 99%

Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

et al. 2020

View full text Add to dashboard Cite

Section: Consolidation Treatment With Cht or Autologous Hctmentioning

confidence: 99%

Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

et al. 2020

View full text Add to dashboard Cite

“…The development of highly sensitive and specific MRD assessment methods seems to lead to the rejuvenation of the concept of autologous transplantation in AML. Autologous transplantation can potentially allow a selected group of patients, especially with low and potentially intermediate genetic risk, to avoid over-treatment with allogeneic transplantation, providing 50–60% probability of long-term LFS [74]. The recently published excellent outcomes of autologous transplantation in MRD negative patients with low or intermediate genetic risk [75,76,77,78] prompt re-evaluating the role of autologous transplantation in AML.…”

Section: The Role Of Mrd In Hsct For Amlmentioning

confidence: 99%

The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia

Czyż

Nagler

2019

IJMS

Self Cite

View full text Add to dashboard Cite

The significance of measurable residual disease (MRD) in hematopoietic stem cell transplantation (HSCT) is well recognized in different hematological malignancies, but the evidence indicate that pre-transplant MRD status is of particular importance in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). In ALL, inadequate response at the level of MRD is a commonly accepted risk factor for relapse and thus an indication for allogeneic HSCT. Similarly, growing evidence from the literature strongly suggest that MRD detected by multiparameter flow cytometry or molecular techniques should be also used for risk stratification in AML at the time of HSCT. Despite the well-defined association of MRD and outcomes of HSCT in acute leukemias, there are still many open issues such as the role of additional pre-transplant consolidation for MRD eradication, the ability of HSCT to overcome negative influence of MRD positivity on survival, the impact of conditioning regimen intensity on MRD clearance post HSCT, and transplantation outcomes or the selection of optimal donor with regards to MRD status. In addition, the role of MRD assessment in guiding post-transplant maintenance treatment should also be addressed in prospective trials. These open issues mostly awaiting further clinical studies will be discussed in our current review.

show abstract

“…Conditioning regimen was based on busulfan plus melphalan, and a median cell dose of 2.72x10 6 /kg of body weight (range 0.52 to 32.5) CD34+ was administered. Gorin et al reported a 2-year LFS of 61 % with auto-HSCT following the same busulfan plus -melphalan conditioning [20]. In our study the 5-year overall survival probability is 60.8%, and median overall survival was not reached (see Figure 2).…”

Section: Discussionmentioning

confidence: 39%

Autologous hematopoietic stem cell transplantation for acute myeloid leukemia – single center experience

Simancikova¹,

Bojtárová²,

Hrubisko³

et al. 2017

neo

View full text Add to dashboard Cite

We aimed to determine the effect of autologous hematopoietic stem cell transplantation (auto-HSCT) on acute myeloid leukemia (AML) patients as a valid alternative therapeutic option for patients without HLA-compatible donor. This retrospective single center study included 79 patients with AML older than 18 years. In this report, we describe the patient characteristics, engraftment, toxicity of treatment, complications, overall survival, and relapse incidence of 79 patients treated chemotherapy and followed by auto-HSCT. The descriptive statistics was used, and the method of Kaplan and Meier was applied to calculate the actuarial rate of overall survival. The patients achieved an absolute neutrophile count (ANC) of ≥ 0.5 x109/l in between 10 to 40 days; median was 14 days after auto-HSCT. The patients achieved platelet count ≥ 20 x109/l in between 10 to 209 days; median was 19 days after auto-HSCT. Hundred-day mortality after autologous transplant was 6.57% (5/76). The relapse rate was 39.5% (32 patients) and 7 patients (8.6%) were lost from follow-up. On the date of evaluation (April 30, 2016), 48 patients (60.8%) were alive, including 7 (8.6%) patients who are lost from follow-up (not responding to check-up request). The 5-year overall survival (OS) was 60.8%; median overall survival was not reached. The present clinical study has demonstrated safety and efficacy of myeloablative chemotherapy followed by auto-HSCT in the treatment of AML in first remission.

show abstract

Abstract: In patients with AML in first complete remission who undergo ASCT, the BUMEL combination is a better preparative regimen. Cancer 2017;123:824-31. © 2016 American Cancer Society.

Cited by 34 publications

References 39 publications

Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia

Autologous hematopoietic stem cell transplantation for acute myeloid leukemia – single center experience

Contact Info

Product

Resources

About